Effects of Sacubactril Valsartan on Cardiac Function,Exercise Endurance and Safety in Patients with Heart Failure with Preserved Ejection Fraction
Objective To analyze the clinical effect of sacubactril valsartan in treating heart failure with preserved ejection fraction(HFpEF).Methods A total of 120 HFpEF patients admitted in Nanjing Gaochun People's Hospital from January to November 2022 were selected and divided into two groups according to random number table method,with 60 cases in each group,and all of them were given routine clinical treatment.The control group was treated with valsartan capsule,and the observation group was treated with sacubactril valsartan.The efficacy and safety of the two groups were evaluated.Results After 6 months of treatment,indicators of cardiac function in the observation group were better than those in the control group and the differences were statistically significant(all P<0.05).The 6 min walking distance of the observation group was significantly longer than that of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse drug reactions between the two groups(P>0.05).The re-hospitalization rate of the observation group was 1.67%,lower than that of the control group(13.33%),and the difference was statistically significant(χ2=4.324,P<0.05).Conclu-sion HFpEF patients treated with sacubactril valsartan can significantly improve their heart function,improve exercise endurance,and reduce the rate of heart failure rehospitalization.
Heart failure with preserved ejection fractionSacubactril valsartanHeart functionSports enduranceDrug safety
万方数据
维普
